产品详情
简单介绍：
Anti-MCP-2抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-MCP-2抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
详情介绍：
Rabbit Anti-MCP-2
Cat. Number:
Anti-MCP-2抗体KL-1984R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
This gene is one of several cytokine genes clustered on the q-arm of chromosome 17. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The protein encoded by this gene is structurallyAnti-MCP-2抗体 related to the CXC subfamily of cytokines. Members of this subfamily are characterized by two cysteines separated by a single amino acid. This cytokine displays chemotactic activity for monocytes, lymphocytes, basophils and eosinophils. By recruiting leukocytes to sites of inflammation this cytokine may contribute to tumor-associated leukocyte infiltration and to the antiviral state against HIV infection. [provided by RefSeq, Jul 2008].
Also known as:
MCP2; CCL 8; CCL8; CCL8; CCL8_HUMAN; C-C motif chemokine 8; Chemokine CC Motif Ligand 8; Chemokine CC Motif Ligand 8; HC14; Anti-MCP-2抗体HC14; MCP-2; MCP-2(6-76); Monocyte chemoattractant protein 2; Monocyte Chemotactic Protein 2; Monocyte Chemotactic Protein 2; SCYA10; SCYA8; SCYA8; Small inducible cytokine A8 [Precursor]; Small-inducible cytokine A8.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Rat, .Anti-MCP-2抗体
●
Immunogen: KLH conjugated synthetic peptide derived from human MCP-2.
●
Predicted Molecular Weight: 8/9kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-MCP-2抗体
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-MCP-2抗体
Optimal working dilutions must be determined by the end user.
